<DOC>
	<DOCNO>NCT02176291</DOCNO>
	<brief_summary>The purpose project examine feasibility , safety , tolerability clinical effect low-dose buprenorphine novel treatment late-life treatment-resistant depression develop preliminary data mechanism action .</brief_summary>
	<brief_title>Incomplete Response Late-Life Depression : Getting Remission With Buprenorphine</brief_title>
	<detailed_description>Up one half old patient major depression develop Late-Life Treatment Resistant Depression ( LL-TRD ) . Consequences LL-TRD include suicide , worsen medical condition , increase caregiver burden , high all-cause mortality . The development test novel-mechanism pharmacotherapies public health priority embrace NIMH . Among neuropeptidergic transmitter , opioids know modulate mood , system often alter patient major depression . Targeting opiate system LL-TRD may positively modulate system age-associated imbalance circulate opiate density bind affinity mu kappa opiate receptor . Buprenorphine ( BPN ) antagonist kappa opiate receptor partial agonist mu opiate receptor . Either , , pharmacodynamic action may underlie putative antidepressant effect . Our research group open pilot data 15 old adult prospectively demonstrate treatment resistance venlafaxine expose low-dose BPN , suggest clinically meaningful antidepressant effect . In addition , since BPN : 1 ) available sublingual formulation 2 ) favorable safety pharmacokinetic profile , attractive candidate re-purpose molecule LL-TRD . Thus , overarch aim project examine feasibility , safety , tolerability clinical effect low-dose BPN novel treatment LL-TRD develop preliminary data mechanism action ( MOA ) . The overarch aim examine feasibility , safety , tolerability buprenorphine ( BPN ) novel treatment late-life treatment resistant depression ( LL-TRD ) . This also involve use translational tool modern neurobiology ( fMRI ) rapidly obtain proof-of-concept support clinical development . Formal dosing schedule use buprenorphine yet thoroughly establish . This study hop determine optimal dosing strategy improve acceptability .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>1 . Age &gt; /= 50 year . 2 . Major depressive disorder ( MDD ) , single recurrent , diagnose SCIDIV . 3 . MADRS &gt; /= 15 . 4 . Has agree establish clinical relationship primary care physician ( PCP ) . 5 . Availability informant ( e.g. , emergency contact ) . 1 . Inability provide inform consent . 2 . Depressive symptom severe enough ( i.e. , MADRS &lt; 15 ) baseline assessment . 3 . Dementia , define 3MS &lt; 84 clinical evidence dementia ( e.g. , memory impairment , executive dysfunction , agnosia , apraxia , aphasia , functional impairment ) . 4 . Lifetime diagnosis bipolar I II disorder , schizophrenia , schizoaffective disorder , schizophreniform disorder , delusional disorder , current psychotic symptom , diagnose SCID . 5 . Abuse dependence alcohol substance within past 3 month determine SCID , confirm study physician interview . 6 . Alcohol use amount 15 drink per week drinking 5 drink one occasion give week . 7 . High risk suicide ( e.g. , active SI and/or current/recent intent plan ) AND unable manage safely clinical trial ( e.g. , unwilling hospitalize ) . Urgent psychiatric referral make case . 8 . Contraindication venlafaxine XR BPN determine study physician include history intolerance either venlafaxine XR BPN study target dosage range ( venlafaxine XR 300 mg/day ; BPN 2 mg/day ) . 9 . Inability communicate English ( i.e. , interview conduct without interpreter ; subject largely unable understand question respond English ) . 10 . Noncorrectable clinically significant sensory impairment ( i.e. , hear well enough cooperate interview ) . 11 . Unstable medical illness , include delirium , uncontrolled diabetes mellitus , hypertension , cerebrovascular cardiovascular risk factor medical management . This determine base information patient 's personal physician study physician 's clinical judgment . Referral patient 's personal physician general practitioner make case . Sodium glucose level do past 6 month also review subject begin study medication determine illness stable uncontrolled . Individual lab parameter may deviate normal without associated pathophysiology negative clinical affect ; therefore follow guide begin start study medication . Sodium value 135 asymptomatic= consider normal proceed without test . Sodium value 134= repeat sodium . If value continue 134 high subject asymptomatic , continue study participation recheck sodium level one week exposure study medication confirm stay stable . Sodium value 133 less= evaluate subject 's medication list suggest possibly remove medication may contribute low sodium ( collaboration PCP ) , suggest fluid restriction require repeat sodium normal range prior commence study . Glucose &lt; 275 asymptomatic= stable proceed communicate value PCP participant permission . ( see exclusion # 17 information hepatic function lab parameter ) 12 . Subjects take psychotropic medication safely taper discontinue prior study initiation . The following exception allow take stable dose least 4 week prior study entry plan change dose next 28 week : benzodiazepine 2 mg/d lorazepam equivalent ; sedativehypnotics ( e.g. , zolpidem , zaleplon , eszopiclone ) ; gabapentin prescribed nonpsychiatric indication ( e.g. , neuropathy ) . 13 . History opiate abuse dependence . 14 . Severe pain , define &gt; /= 7 010 numeric rating scale pain . 15 . Concomitant use strong moderate CYP3A4 inhibitor ( indinavir , nelfinavir , ritonavir , clarithromycin , itraconazole , ketonazole , nefazodone , saquinovir , telithromycin , aprepitant , erythromycin , fluconazole , grapefruit juice , verapamil , diltiazem ) 16 . Refusal stop opioids ( avoid precipitate opioid withdrawal ) . 17 . Hepatic impairment ( AST/ALT &gt; 1.5 time upper normal ) . If AST ALT within 1.5 time upper limit , subject asymptomatic , consider medically stable participate 18 . Estimated Glomerular Filtration Rate ( GFR ) &lt; 20 ml/min . 19 . Inability/refusal identify person emergency contact . 20 . Pregnancy 21 . Contraindications MRI</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Buprenorphine</keyword>
	<keyword>Receptors , opioid</keyword>
	<keyword>Receptors , opioid kappa mu</keyword>
</DOC>